Blockchain Registration Transaction Record

Oncotelic's Nano Platform Shows Versatility in Delivering Complex Cancer Drugs

Oncotelic's joint venture Sapu Nano reveals data showing its Deciparticle platform can formulate diverse cancer drugs into nanoparticles, enabling new IV therapies.

This development matters because it addresses a critical bottleneck in modern drug development: delivering complex, often insoluble, therapeutic molecules effectively to their target in the body. Many promising drug candidates fail not because they lack biological activity, but because they cannot be formulated into a stable, deliverable form. The Deciparticle platform's ability to consistently package diverse hydrophobic compounds into tiny, IV-ready nanoparticles could unlock a new wave of treatments for cancers and other diseases. For patients, this translates to potential access to more effective therapies that were previously stuck in the lab. For the biopharma industry, it represents a valuable tool to accelerate the translation of novel discoveries from bench to bedside, potentially improving success rates in clinical trials and bringing new options to market faster.